Application of streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of product for treating adenoid body inflammation

Abstract

The invention discloses an application of a streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of a product for treating adenoid body inflammation. The preservation number of the streptococcus salivarius subsp. Thermophilus Biohalo 23 is DSM34540; the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for relieving the disease symptom of adenoid body inflammation and reducing the incidence rate of adenoid body inflammation, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention has a remarkable curative effect on adenoid body inflammation, and particularly, through clinical tests, the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet has a remarkable curative effect on adenoid body inflammation. The streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for remarkably improving symptoms such as tachypnea, mouth breathing, snoring, cough, nasal obstruction, hearing loss and the like, and also can be used for reducing the incidence rate of adenoid body inflammation, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for treating the adenoid body inflammation.

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to application of a Streptococcus salivarius thermophilic subspecies Biohalo23 tablet in the preparation of a product for treating adenoids. Background Art

[0002] Adenoids are inflammation of the lymphatic tissue at the top of the nasopharynx. The adenoids are largest at about 6 years old and gradually shrink and degenerate after 10 years old, but a few adults still have residual adenoids.

[0003] Repeated stimulation of inflammation of the nasopharynx and its adjacent parts or inflammation of the adenoids themselves causes pathological proliferation of the adenoids. Common causes include repeated attacks of acute and chronic nasopharyngitis, various acute infectious diseases in childhood, etc. Inflammation of the nose and sinuses can also affect the adenoids through their mucosa; conversely, enlarged adenoids can block the posterior nasal cavity and aggravate inflammation of the nose and sinuses. This disease is prone to occur in cold and humid areas, so cold and dampness may be its cause.

[0004] Children may experience otorhinolaryngology and other symptoms due to the blockage of the posterior nasal cavity and the pharyngeal opening of the Eustachian tube by enlarged adenoids. The symptoms include open-mouth breathing during sleep, snoring with the tongue root falling back, restless sleep at night, excessive nasal secretions, occlusal nasal sounds when speaking, and slurred speech. Long-term open-mouth breathing causes developmental disorders of the facial bones, elongated maxilla, high arched hard palate, irregular dentition, exposed upper incisors, thick lips, lack of facial expression, dementia, and the formation of an "adenoid face". Ataxia between swallowing and breathing often causes choking and coughing. The secretions flow down to irritate the respiratory mucosa, making it easy to suffer from tracheitis. The obstruction of the Eustachian tube can easily cause non-suppurative otitis media, resulting in decreased suction and retraction of the tympanic membrane.

[0005] At present, the general treatment for adenoids in clinical practice is that if the symptoms are mild, they can be relieved by adjusting diet, improving lifestyle habits, etc. It is recommended to eat a light diet, eat more vegetables and fruits, and eat less spicy and irritating foods. Pay attention to rest, avoid staying up late or catching cold, so as not to aggravate the inflammation; Drug treatment: If the inflammation of the adenoids cannot heal itself, you can take drug treatment under the guidance of a doctor, such as taking ribavirin tablets, amoxicillin capsules, cefixime dispersible tablets, erythromycin capsules and other drugs; Surgical treatment: If the drug treatment is not effective, you can go to the hospital and undergo adenoidectomy under the guidance of a doctor after evaluation; then, surgical treatment is likely to lead to hearing loss and throat discomfort, while the drug treatment effect is not ideal and has certain side effects on the body.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The object of the present invention is to provide an application of a thermophilic Streptococcus salivarius subspecies Biohalo23 tablet in the preparation of a product for treating adenoids. The thermophilic Streptococcus salivarius subspecies Biohalo23 tablet of the present invention can alleviate the symptoms of adenoids and reduce the incidence of adenoids. Therefore, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablet of the present invention has a significant therapeutic effect on adenoids.

[0008] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0009] The first aspect of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in the preparation of a product for treating adenoids, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0010] The second aspect of the present invention provides a probiotic tablet, which comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0011] Preferably, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0012] Preferably, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0013] Preferably, the auxiliary materials consist of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0014] Preferably, the flavor includes strawberry flavor, apple flavor or orange flavor.

[0015] Preferably, the mass of each probiotic tablet is 0.9-1 g.

[0016] Compared with the prior art, the beneficial effects of the present invention include at least:

[0017] The thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can alleviate the symptoms of adenoids and reduce the incidence of adenoids. Therefore, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention have significant therapeutic effects on adenoids. Specifically, through clinical trials, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can significantly improve symptoms such as shortness of breath, mouth breathing, snoring, coughing, nasal congestion, hearing loss, etc., and can reduce the incidence of adenoids, thereby indicating that the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can be used for the treatment of adenoids.

[0018] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects. DETAILED DESCRIPTION

[0019] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0020] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0021] The embodiment of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in preparing a product for treating adenoids. The Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0022] The preservation unit of the thermophilic subspecies Biohalo23 of Streptococcus salivarius of the present invention is the German Microorganisms Preservation Center, and the strain can be purchased from the German Microorganisms Preservation Center.

[0023] The thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can alleviate the symptoms of adenoids and reduce the incidence of adenoids. Therefore, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention have significant therapeutic effects on adenoids. Specifically, through clinical trials, the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can significantly improve symptoms such as shortness of breath, mouth breathing, snoring, coughing, nasal congestion, hearing loss, etc., and can reduce the incidence of adenoids, thereby indicating that the thermophilic Streptococcus salivarius subspecies Biohalo23 tablets of the present invention can be used for the treatment of adenoids.

[0024] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects.

[0025] Another embodiment of the present invention provides a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0026] By adding auxiliary materials, the activity of the thermophilic subspecies of Streptococcus salivarius Biohalo23 can be better preserved, and the taste of the product can be improved, thereby improving the taste of the probiotic tablets for children.

[0027] In one embodiment, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0028] By limiting the content of the thermophilic subspecies Biohalo23 of Streptococcus salivarius in probiotic tablets, the efficacy of the probiotic tablets can be better improved.

[0029] In one embodiment, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0030] In some embodiments, the auxiliary materials are composed of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0031] In one embodiment, the flavor includes strawberry flavor; in other embodiments, the flavor may be strawberry flavor, apple flavor or orange flavor.

[0032] In one embodiment, the mass of each probiotic tablet is 0.9-1 g.

[0033] The technical scheme of the present invention is further described in detail below through specific examples. The various materials and reagents used in the following specific examples are commonly used materials and reagents in the field and can be obtained through regular commercial channels; the methods used are conventional methods known to those skilled in the art.

[0034] Example 1

[0035] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0036] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0037] The auxiliary materials consist of 10 parts of crystalline fructose, 88 parts of maltodextrin, 0.8 parts of magnesium stearate and 0.2 parts of flavor, wherein the flavor is strawberry flavor.

[0038] Example 2

[0039] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0040] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0041] The auxiliary materials consist of 15 parts of crystalline fructose, 82 parts of maltodextrin, 1.2 parts of magnesium stearate and 0.8 parts of flavor, wherein the flavor is strawberry flavor.

[0042] Example 3

[0043] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0044] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0045] The auxiliary materials consist of 12 parts of crystalline fructose, 85.5 parts of maltodextrin, 1 part of magnesium stearate and 0.5 parts of flavor, wherein the flavor is strawberry flavor.

[0046] Experimental example

[0047] This experimental example is a study on the effect of Streptococcus salivarius thermophilus subspecies Biohalo23 (German strain library deposit number DSM34540) on adenoids;

[0048] The probiotic tablets used in the following experiments are the probiotic tablets prepared in Example 3.

[0049] 1. A total of 219 children diagnosed with chronic adenoids were recruited for the experiment, of which 113 children took probiotic tablets for 30 days accompanied by nasal irrigation, and 106 children only used nasal irrigation for conservative treatment as the control group, and were followed up for 90 days.

[0050] Experimental results:

[0051] Compared with the control group, the incidence of adenoids decreased by 44% during the period when the children took the probiotic tablets;

[0052] The incidence of acute adenoids in children decreased by 74% during the follow-up period.

[0053] 2. A total of 57 children diagnosed with recurrent adenoids were recruited; they were randomly divided into a probiotic tablet group and a control group. There were 36 children in the probiotic tablet group who took probiotic tablets for 30 consecutive days, and the other 21 children who did not take probiotic tablets served as the control group. They were followed up for 5 months.

[0054] Experimental results:

[0055] Compared with the same period of the previous year, the incidence of adenoids in children taking probiotic tablets decreased by 85% during the entire clinical observation period (P<0.05), and the incidence in the control group was not significantly different from the previous year (P>0.05). Related characteristics such as shortness of breath, open mouth breathing and snoring during sleep, coughing (mainly at night and in the morning), nasal congestion, and hearing loss showed significant improvement from the 10th day of the study. Compared with the control group, the total index of children taking probiotic tablets during the period of significant improvement was about 2 times.

[0056] In summary, taking probiotic tablets can significantly improve symptoms such as shortness of breath, mouth breathing, snoring, coughing, nasal congestion, hearing loss, etc., and can reduce the incidence of adenoids, which further indicates that the thermophilic subspecies of Streptococcus salivarius Biohalo23 tablets of the present invention can be used for the treatment of adenoids.

[0057] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. Application of Streptococcus salivarius thermophilus subspecies Biohalo23 tablets in the preparation of a product for treating adenoids, characterized in that: The thermophilic Streptococcus salivarius subspecies Biohalo23 is deposited with DSM34540.

2. A probiotic tablet, characterized in that: The probiotic tablet comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 according to claim 1 and auxiliary materials.

3. The probiotic tablet according to claim 2, characterized in that The content of the thermophilic Streptococcus salivarius subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

4. The probiotic tablet according to claim 2, characterized in that The auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

5. The probiotic tablet according to claim 2, characterized in that: The auxiliary material consists of 10-15 parts of crystal fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

6. The probiotic tablet according to claim 4, characterized in that: The flavor includes strawberry flavor, apple flavor or orange flavor.

7. The probiotic tablet according to claim 2, characterized in that: The mass of each probiotic tablet is 0.9-1g.